Carina Biotech is delighted to announce it has raised AU$5.4 million. The raise was strongly supported by current shareholders, board and management and attracted new institutional and impact investors including a cornerstone
Carina Biotech has entered a collaboration agreement with Melbourne biotech AdAlta to develop precision engineered, i-body enabled CAR-T therapies that provide new hope for patients with cancer. To learn more, watch
Emma Thompson is a PhD candidate in Professor Claudine Bonder's Vascular Biology & Cell Trafficking Laboratory at UniSA's Centre for Cancer Biology. Emma's research is focused on testing Carina Biotech's LGR5-targeting CAR-T
Story by Hayden Smith, featured in The Weekend Australian, 5 June 2021 Battling blood cancer in my 20s, I put my faith in a clinical trial for a promising new
Colorectal cancer, also known as bowel cancer, colon cancer or rectal cancer, affects men and women, young and old. Australia has one of the highest rates of colorectal cancer in
Carina Biotech has welcomed to its team two new staff members – Professor Shaun McColl and Dr José Iglesias MD. These two experts in immunology, T cell biology, oncology and
Dr Deborah Rathjen After completing its first (and second) commercial deals in the middle of last year, Carina is now rapidly transitioning from CAR-T discovery company to an emerging clinical
Carina Biotech scientist Dr Veronika Bandara presented data at this week's Eradicate Cancer Conference on Carina's latest CAR-T cab off the rank that has demonstrated significant killing of two colorectal
In this worldwide exclusive agreement, Carina Biotech will create Chimeric Antigen Receptor T cells (CAR-T cells) and other adoptive cell therapies to the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)
Carina Biotech and UniSA today announced they have developed a new device to improve cancer immunotherapies. Our researchers at the University of South Australia have developed a novel approach based
